SLGL
Sol-Gel Technologies Ltd.
Biotechnology
Market Cap$194M
5Y Perf.-9.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SLGL vs VYNE
Revenue, margins, valuation, and 5-year total return — side by side.
VYNE
VYNE Therapeutics Inc.
Biotechnology
Market Cap$29M
5Y Perf.-99.6%
SLGL vs VYNE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SLGL | VYNE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $194M | $29M |
| Revenue (TTM) | $7M | $570K |
| Net Income (TTM) | $-15M | $-26M |
| Gross Margin | -153.5% | 99.1% |
| Operating Margin | -256.2% | -52.2% |
| Total Debt | $991K | $0.00 |
| Cash & Equiv. | $11M | $24M |
SLGL vs VYNE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SLGL
VYNE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Sol-Gel Technologie… (SLGL) | 100 | 90.1 | -9.9% |
| VYNE Therapeutics I… (VYNE) | 100 | 0.4 | -99.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLGL vs VYNE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SLGL leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SLGL
Sol-Gel Technologies Ltd.
The Growth Play
SLGL carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 68.0%, EPS growth -478.9%, 3Y rev CAGR 70.9%
- -49.0% 10Y total return vs VYNE's -100.0%
- 68.0% revenue growth vs VYNE's 13.8%
Best for: growth exposure and long-term compounding
VYNE
VYNE Therapeutics Inc.
The Defensive Pick
VYNE is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.74, current ratio 12.53x
- Beta 0.74, current ratio 12.53x
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLGL | 68.0% revenue growth vs VYNE's 13.8% |
| Quality / Margins | SLGL | -227.4% margin vs VYNE's -46.5% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SLGL | +8.0% vs VYNE's -50.8% |
| Efficiency (ROA) | SLGL | -33.7% ROA vs VYNE's -63.3%, ROIC -48.6% vs -124.0% |
SLGL vs VYNE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
SLGL vs VYNE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSLGLLAGGINGVYNE
VYNEVYNE Therapeutics Inc.
0leads
SLGLSol-Gel Technologies …
5leads
6 Total Categories
CATEGORYLEADERvs VYNEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SLGL5/6
Valuation MetricsMultiples, price ratios, and targets
SLGL2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SLGL5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
SLGL6/6
Risk & VolatilityBeta, volatility, and downside exposure
SLGL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SLGL leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SLGL is the larger business by revenue, generating $7M annually — 11.5x VYNE's $570,000. SLGL is the more profitable business, keeping -2.3% of every revenue dollar as net income compared to VYNE's -46.5%. On growth, SLGL holds the edge at +8.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $570,000 |
| EBITDAEarnings before interest/tax | -$16M | -$30M |
| Net IncomeAfter-tax profit | -$15M | -$26M |
| Free Cash FlowCash after capex | $0 | -$33M |
| Gross MarginGross profit ÷ Revenue | -153.5% | +99.1% |
| Operating MarginEBIT ÷ Revenue | -2.6% | -52.2% |
| Net MarginNet income ÷ Revenue | -2.3% | -46.5% |
| FCF MarginFCF ÷ Revenue | +1.4% | -58.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.1% | +54.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +132.2% | +57.1% |
SLGL leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
SLGL leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… |
|---|---|---|
| Market CapShares × price | $194M | $29M |
| Enterprise ValueMkt cap + debt − cash | $184M | $5M |
| Trailing P/EPrice ÷ TTM EPS | -31.61x | -1.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.99x | 50.53x |
| Price / BookPrice ÷ Book value/share | 8.49x | 1.04x |
| Price / FCFMarket cap ÷ FCF | 704.54x | — |
SLGL leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
SLGL leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
SLGL delivers a -40.0% return on equity — every $100 of shareholder capital generates $-40 in annual profit, vs $-74 for VYNE. On the Piotroski fundamental quality scale (0–9), SLGL scores 7/9 vs VYNE's 2/9, reflecting strong financial health.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | -40.0% | -74.1% |
| ROA (TTM)Return on assets | -33.7% | -63.3% |
| ROICReturn on invested capital | -48.6% | -124.0% |
| ROCEReturn on capital employed | -28.0% | -74.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 |
| Debt / EquityFinancial leverage | 0.04x | — |
| Net DebtTotal debt minus cash | -$10M | -$24M |
| Cash & Equiv.Liquid assets | $11M | $24M |
| Total DebtShort + long-term debt | $991,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
SLGL leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
SLGL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SLGL five years ago would be worth $7,289 today (with dividends reinvested), compared to $103 for VYNE. Over the past 12 months, SLGL leads with a +800.8% total return vs VYNE's -50.8%. The 3-year compound annual growth rate (CAGR) favors SLGL at 24.5% vs VYNE's -57.3% — a key indicator of consistent wealth creation.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | +65.0% | +16.1% |
| 1-Year ReturnPast 12 months | +800.8% | -50.8% |
| 3-Year ReturnCumulative with dividends | +93.2% | -92.2% |
| 5-Year ReturnCumulative with dividends | -27.1% | -99.0% |
| 10-Year ReturnCumulative with dividends | -49.0% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +24.5% | -57.3% |
SLGL leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SLGL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SLGL is the less volatile stock with a -0.18 beta — it tends to amplify market swings less than VYNE's 0.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SLGL currently trades 71.0% from its 52-week high vs VYNE's 34.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.18x | 0.74x |
| 52-Week HighHighest price in past year | $97.97 | $1.96 |
| 52-Week LowLowest price in past year | $6.57 | $0.28 |
| % of 52W HighCurrent price vs 52-week peak | +71.0% | +34.4% |
| RSI (14)Momentum oscillator 0–100 | 45.9 | 68.7 |
| Avg Volume (50D)Average daily shares traded | 42K | 192K |
SLGL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SLGLSol-Gel Technolog… | VYNEVYNE Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $50.00 | — |
| # AnalystsCovering analysts | 6 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SLGL leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallSol-Gel Technologies Ltd. (SLGL)Leads 5 of 6 categories
Loading custom metrics...
SLGL vs VYNE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SLGL or VYNE a better buy right now?
For growth investors, Sol-Gel Technologies Ltd.
(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus 13. 8% for VYNE Therapeutics Inc. (VYNE). Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SLGL or VYNE?
Over the past 5 years, Sol-Gel Technologies Ltd.
(SLGL) delivered a total return of -27. 1%, compared to -99. 0% for VYNE Therapeutics Inc. (VYNE). Over 10 years, the gap is even starker: SLGL returned -49. 0% versus VYNE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SLGL or VYNE?
By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.
(SLGL) is the lower-risk stock at -0. 18β versus VYNE Therapeutics Inc. 's 0. 74β — meaning VYNE is approximately -520% more volatile than SLGL relative to the S&P 500.
04Which is growing faster — SLGL or VYNE?
By revenue growth (latest reported year), Sol-Gel Technologies Ltd.
(SLGL) is pulling ahead at 68. 0% versus 13. 8% for VYNE Therapeutics Inc. (VYNE). On earnings-per-share growth, the picture is similar: VYNE Therapeutics Inc. grew EPS 34. 0% year-over-year, compared to -478. 9% for Sol-Gel Technologies Ltd.. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SLGL or VYNE?
Sol-Gel Technologies Ltd.
(SLGL) is the more profitable company, earning -31. 6% net margin versus -46. 5% for VYNE Therapeutics Inc. — meaning it keeps -31. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLGL leads at -39. 2% versus -52. 2% for VYNE. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SLGL or VYNE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SLGL or VYNE better for a retirement portfolio?
For long-horizon retirement investors, Sol-Gel Technologies Ltd.
(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 18)). Both have compounded well over 10 years (SLGL: -49. 0%, VYNE: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SLGL and VYNE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SLGL is a small-cap high-growth stock; VYNE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SLGL: 814.6% · VYNE: 54.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.